Literature DB >> 18004522

[Systemic treatment of peritoneal metastases].

D Arnold1, F Lordick.   

Abstract

Peritoneal metastases are common in metastatic disease of many tumour types and thus are determinant for prognosis and development of tumour-related symptoms that jeopardise quality of life. Systemic chemotherapy has proven efficacious in improving both prognosis and quality of life in numerous tumour types and should therefore be considered as part of the treatment strategy--although there is no large body of data from predefined cohorts with"only peritoneal" manifestation. In further clinical trials therefore, improvement of systemic chemotherapy by integration of novel agents should be implemented in multimodal treatment approaches combining systemic treatment, cytoreductive surgery, and intraperitoneal treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18004522     DOI: 10.1007/s00104-007-1435-0

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  18 in total

1.  Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report.

Authors:  M SWERDLOW
Journal:  Am J Obstet Gynecol       Date:  1959-01       Impact factor: 8.661

2.  Potentially curative surgery of colon cancer: patterns of failure and survival.

Authors:  B D Minsky; C Mies; T A Rich; A Recht; J T Chaffey
Journal:  J Clin Oncol       Date:  1988-01       Impact factor: 44.544

3.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Authors:  Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

4.  Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.

Authors:  C H Köhne; D Cunningham; F Di Costanzo; B Glimelius; G Blijham; E Aranda; W Scheithauer; P Rougier; M Palmer; J Wils; B Baron; F Pignatti; P Schöffski; S Micheel; H Hecker
Journal:  Ann Oncol       Date:  2002-02       Impact factor: 32.976

5.  Serous surface carcinoma of the peritoneum: a clinicopathologic study of 22 cases.

Authors:  L D Truong; M L Maccato; H Awalt; P T Cagle; M R Schwartz; A L Kaplan
Journal:  Hum Pathol       Date:  1990-01       Impact factor: 3.466

Review 6.  Management of pseudomyxoma peritonei.

Authors:  Zhi-Bo Qu; Lian-Xin Liu
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

7.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

8.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.

Authors:  Vic J Verwaal; Serge van Ruth; Eeclo de Bree; Gooike W van Sloothen; Harm van Tinteren; Henk Boot; Frans A N Zoetmulder
Journal:  J Clin Oncol       Date:  2003-10-15       Impact factor: 44.544

9.  Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.

Authors:  G Folprecht; D Cunningham; P Ross; B Glimelius; F Di Costanzo; J Wils; W Scheithauer; P Rougier; E Aranda; H Hecker; C-H Köhne
Journal:  Ann Oncol       Date:  2004-09       Impact factor: 32.976

10.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.